ATE464065T1 - Neue medizinische verwendung von alpha-antigen oder alpha-antigen-gen - Google Patents

Neue medizinische verwendung von alpha-antigen oder alpha-antigen-gen

Info

Publication number
ATE464065T1
ATE464065T1 AT02700618T AT02700618T ATE464065T1 AT E464065 T1 ATE464065 T1 AT E464065T1 AT 02700618 T AT02700618 T AT 02700618T AT 02700618 T AT02700618 T AT 02700618T AT E464065 T1 ATE464065 T1 AT E464065T1
Authority
AT
Austria
Prior art keywords
alpha antigen
allergic
medical use
new medical
diseases
Prior art date
Application number
AT02700618T
Other languages
English (en)
Inventor
Yasuhiro Yasutomi
Hitoshi Mizutani
Original Assignee
Maruho Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maruho Kk filed Critical Maruho Kk
Application granted granted Critical
Publication of ATE464065T1 publication Critical patent/ATE464065T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT02700618T 2001-02-20 2002-02-20 Neue medizinische verwendung von alpha-antigen oder alpha-antigen-gen ATE464065T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001043291 2001-02-20
PCT/JP2002/001459 WO2002066055A1 (fr) 2001-02-20 2002-02-20 Nouvelle utilisation en medecine d'un antigene alpha ou d'un gene d'antigene alpha

Publications (1)

Publication Number Publication Date
ATE464065T1 true ATE464065T1 (de) 2010-04-15

Family

ID=18905480

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02700618T ATE464065T1 (de) 2001-02-20 2002-02-20 Neue medizinische verwendung von alpha-antigen oder alpha-antigen-gen

Country Status (7)

Country Link
US (4) US20040076639A1 (de)
EP (1) EP1369127B1 (de)
JP (1) JP4159362B2 (de)
AT (1) ATE464065T1 (de)
CA (1) CA2443502A1 (de)
DE (1) DE60235971D1 (de)
WO (1) WO2002066055A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1369127B1 (de) * 2001-02-20 2010-04-14 MARUHO Co., Ltd. Neue medizinische verwendung von alpha-antigen oder alpha-antigen-gen
JP5145550B2 (ja) * 2006-09-20 2013-02-20 国立大学法人三重大学 パラインフルエンザ２型ウイルスを用いた医薬組成物
US8045306B2 (en) * 2009-10-16 2011-10-25 Himax Technologies Limited Electrical-overstress protection circuit for an integrated circuit
US20120219582A1 (en) * 2009-11-02 2012-08-30 Mie University Intranasal spray-type tuberculosis vaccine using paramyxovirus vector

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02308793A (ja) * 1989-05-22 1990-12-21 Ajinomoto Co Inc ミコバクテリウム・カンサシ由来のα抗原
EP0400973B1 (de) * 1989-05-31 1996-07-31 Ajinomoto Co., Inc. Sekretorische Expressionsvektoren für Mycobakterien sowie Transformanten
DE4422859C2 (de) * 1994-06-30 2000-10-05 Laves Arzneimittel Gmbh Wäßrige Zellextrakte aus Mykobacterien
EP0951289B1 (de) * 1996-12-18 2005-10-26 Stanford Rook Limited Verwendung von mycobacterium vaccae zur therapie des chronischen müdigkeitssyndrom
CA2284736A1 (en) * 1997-03-28 1998-10-08 Cytoclonal Pharmaceutics, Inc. Mycobacterium recombinant vaccines
PT1009413E (pt) * 1997-09-05 2007-05-31 Univ California Utilização de oligonucleótidos imumoestimulantes para a prevenção ou tratamento da asma.
EP1369127B1 (de) * 2001-02-20 2010-04-14 MARUHO Co., Ltd. Neue medizinische verwendung von alpha-antigen oder alpha-antigen-gen

Also Published As

Publication number Publication date
US20060153880A1 (en) 2006-07-13
JPWO2002066055A1 (ja) 2004-06-17
EP1369127B1 (de) 2010-04-14
JP4159362B2 (ja) 2008-10-01
US20080132463A1 (en) 2008-06-05
EP1369127A1 (de) 2003-12-10
WO2002066055A1 (fr) 2002-08-29
US20040076639A1 (en) 2004-04-22
EP1369127A4 (de) 2008-01-30
DE60235971D1 (de) 2010-05-27
US7524675B2 (en) 2009-04-28
US20090286734A1 (en) 2009-11-19
CA2443502A1 (en) 2002-08-29
US7622297B2 (en) 2009-11-24

Similar Documents

Publication Publication Date Title
DK1703893T3 (da) Hidtil ukendte anti-il13-antistoffer og anvendelser deraf
NO20092639L (no) 4-fenyl-6-(2,2,2-trifluor-1-fenyletoksy)pynmidinbaserte forbindelser og anvendelser derav
GB0117326D0 (en) Napthoquinone-type inhibitors of protein aggregation
ATE362928T1 (de) 2-(1h-indazol-6-ylamino)- benzamid-verbindungen als protein kinase inhibitoren und deren verwendung zur behandlung von ophthalmischen krankheiten
NO20052928L (no) Nye kjemiske forbindelser
ATE396731T1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
EP1555028A4 (de) Antiallergisches mittel, seine verwendung zur verringerung von allergien und verfahren zur verringerung von allergien
DE60234523D1 (de) Alpha-amylasevariante mit veränderten eigenschaften
DE69620306D1 (de) 4-(.Alpha.-hydroxy-.alpha.-aryl-alkylcarbonylamino)-Piperidine zur Behandlung und Prophylaxe von Erkrankungen der Harnwege
DE60033530D1 (de) Humane antikörper gegen ctla-4 und deren verwendungen
ATE386106T1 (de) Rekombinante poxvirus-cytomegalovirus zusammensetzungen und ihre verwendung
EP1644514A4 (de) Temperaturstabile amylase-polypeptide, für diese polypeptide codierende nukleinsäuren und verwendungen davon
ATE525480T1 (de) Verwendung von a33-antigenen und jam-it
ATE534635T1 (de) N-pyrazinyl-phenylsulfonamide und deren verwendung zur behandlung von durch chemokine vermittelten krankheiten
ATE336996T1 (de) Verwendung von flavonoid-derivaten zur behandlung von atopischem ekzem
BR0315644A (pt) Piperazinil e diazapanil benzamidas e benzotioamidas
DE60235971D1 (de) Neue medizinische verwendung von alpha-antigen oder alpha-antigen-gen
ATE402924T1 (de) Pyridiniumsalze und deren verwendung
BR0315344A (pt) Métodos para prever edema como um efeito colateral do tratamento com drogas
ATE443135T1 (de) Fluoreszenzprotein und pigmentprotein
ATE324446T1 (de) Mutante formen von etxb und ctxb und ihre verwendung als träger
ATE333452T1 (de) 4-(penylpiperidin-4-ylidenmethyl)benzamidderiva e und deren verwendung zur behandlung von schmerzen,angstzuständen oder erkrankungen des magen-darm- trakts
DE60118898D1 (de) Verwendung von rekombinantem lungensurfactant zur frühbehandlung von akuten lungenerkrankungen
ATE349530T1 (de) Nukleinsäuren und proteine des mph3 gens aus mycoplasma hypopneumoniae und deren verwendung
NO20060781L (no) Anvendelse av loselig CD164 ved inflammatoriske og/eller autoimmune lidelser

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties